NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

10100	Companies
206831	Keywords
136975	Articles
109619	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 07/14/2025 at 12:30, 8 months 12 days ago

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
NanoViricides, Inc. announces design completion of adaptive clinical trial protocol for MPox Virus treatment. Trial to evaluate dosing regimen, safety, and effectiveness in 80 patients

NV-387 Clinical Trial NanoViricides Inc. Antiviral Mpox Virus
BRIEF

published on 07/01/2025 at 12:35, 8 months 25 days ago

NanoViricides fait passer le NV-387 en phase II pour le traitement MPox

NV-387 Essai De Phase II Médicaments Antiviraux Traitement MPox Réserve Stratégique
BRIEF

published on 07/01/2025 at 12:35, 8 months 25 days ago

NanoViricides Advances NV-387 to Phase II for MPox Treatment

NV-387 Antiviral Drugs Phase II Trial MPOX Treatment Strategic Stockpile
PRESS RELEASE

published on 07/01/2025 at 12:30, 8 months 25 days ago

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
NanoViricides, Inc. announces advancing lead candidate NV-387 into Phase II clinical development for MPox. Protocol development and site addition underway in the DRC. Focus on antiviral drug against MPox/Smallpox

NV-387 NanoViricides Inc. Antiviral Drug Mpox Phase II
BRIEF

published on 06/18/2025 at 12:35, 9 months 8 days ago

NanoViricides Presents NV-387 as Leading Antiviral Defense

Pandemic Preparedness NV-387 Antiviral COVID Variants Bird Flu Threat Broad-spectrum Efficacy
BRIEF

published on 06/18/2025 at 12:35, 9 months 8 days ago

NanoViricides présente le NV-387 comme un antiviral de premier plan

Antiviral NV-387 Variantes De La COVID Menace De Grippe Aviaire Efficacité À Large Spectre Préparation Aux Pandémies
PRESS RELEASE

published on 06/18/2025 at 12:30, 9 months 8 days ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
NanoViricides, Inc. announces the effectiveness of broad-spectrum antiviral drug NV-387 against COVID variants and Bird Flu, positioning it well for pandemic preparedness

NanoViricides NV-387 Antiviral Drug Bird Flu COVID Variants
BRIEF

published on 06/04/2025 at 13:00, 9 months 22 days ago

NanoViricides se prépare à une étude animale sur un médicament contre la rougeole

NanoViricides NV-387 Épidémie De Rougeole Déclin Des Vaccins Étude Antivirale
BRIEF

published on 06/04/2025 at 13:00, 9 months 22 days ago

NanoViricides Prepares for Measles Drug Animal Study

NanoViricides NV-387 Measles Outbreak Vaccine Decline Antiviral Study
PRESS RELEASE

published on 06/04/2025 at 12:55, 9 months 22 days ago

NanoViricides Measles Drug Development Animal Study is Imminent
NanoViricides, Inc. announces progress in developing a Measles drug, NV-387, a broad-spectrum antiviral with potential to combat Measles outbreaks and vaccine failures

NV-387 NanoViricides Inc. Antiviral Clinical Stage Measles Drug

Accesswire

Published on 03/26/2026 at 16:20, 2 hours 52 minutes ago

ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 14:05, 5 hours 7 minutes ago

SouthGobi Announces Profit Warning
Published on 03/26/2026 at 13:00, 6 hours 12 minutes ago

Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 6 hours 12 minutes ago

GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 6 hours 13 minutes ago

Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance

View all ACCESSWIRE

EQS Group

Published on 03/26/2026 at 18:57, 14 minutes ago

DSH-Director/PDMR Shareholding
Published on 03/26/2026 at 18:29, 42 minutes ago

IEVA GROUP: IEVA Group is listing on Euronext Growth® Paris to accelerate its growth and innovation strategy
Published on 03/26/2026 at 18:29, 42 minutes ago

IEVA GROUP: IEVA Group entre en bourse sur Euronext Growth pour accélérer sa stratégie de croissance et d’innovation
Published on 03/26/2026 at 18:15, 56 minutes ago

Transaction in Own Shares
Published on 03/26/2026 at 18:13, 59 minutes ago

EQS-Adhoc: Allgeier SE: Allgeier meets its earnings guidance for 2025 and is strengthening its focus on AI-based platform technologies and software solutions

Les Echos

Published on 03/26/2026 at 18:17, 55 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 55 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 1 hour 12 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 1 hour 12 minutes ago

Calendrier financier 2026
Published on 03/26/2026 at 18:00, 1 hour 12 minutes ago

LABORATOIRES EUROMEDIS - Fin du contrat de liquidité

View all LES ECHOS COMFI WIRE